DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering.
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides:
- R&D Spending 2007-2013
- Geographic Breakout of Revenues
- Performance of Specific Products
- Performance by Drug Category
- Late-Stage Pipeline
- Projections of Revenues to 2023
In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities.
The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades.
The companies included in the study are:
- Pfizer, inc.
- Novartis AG
- Roche ltd.
- Merck & Co., inc.
- Glaxosmithkline PLC
- Johnson & johnson
- Astra Zeneca plc
- Eli Lilly and Company
- Abbvie, inc.
- Teva Pharmaceutical Industries, Ltd.
- Amgen, inc.
- Bristol-myers Squibb Company
- Takeda Pharmaceutical co., LTD
- Bayer AG
- Novo nordisk
- Boehringer Ingelheim gmbh
- Daiichi Sankyo
- Gilead Sciences
- Otsuka Pharmaceutical
- Merck KGAA
- Baxter international
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals; diagnostics; devices; chemicals; agriculture; and animal health. Strategic acquisitions and partnerships with biotech companies have allowed traditional pharmaceutical companies an opportunity to become diverse in pipelines and product offerings. Companies like Amgen, which specialize in biotechnology, now compete with a growing number of what the industry has once considered to be the traditional pharmaceutical company, This is a trend expected to continue to grow as interest in the small biotechnology focused companies continue to be acquired by the Pfizer's, Novartis' and Roche's of the industry
Key Topics Covered:
TRENDS IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT
MARKET SUMMARY AND FORECAST ANALYSIS
TABLE OF EXHIBITS
For more information visit http://www.researchandmarkets.com/research/dmbl76/top_25
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets